Recap: Revance Therapeutics Q1 Earnings

Revance Therapeutics RVNC reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM.

Here's what investors need to know about the announcement.

Revance Therapeutics missed estimated earnings by 3.3%, reporting an EPS of $-0.94 versus an estimate of $-0.91.

Revenue was up $11.96 million from the same period last year.

Last quarter the company beat on EPS by $0.09 which was followed by a 12.01% increase in the share price the next day.

Here's a look at Revance Therapeutics's past performance:

Quarter	Q4 2021	Q3 2021	Q2 2021	Q1 2021
EPS Estimate	-1.02	-1.15	-1.05	-1.09
EPS Actual	-0.93	-1.10	-1.07	-1.08
Revenue Estimate	24.27M	20.29M	15.48M	10.98M
Revenue Actual	25.95M	19.75M	18.80M	13.30M

To track all earnings releases for Revance Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar